Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy

J. O. Armitage, M. P. Corder, J. T. Leimert, F. R. Dick, T. E. Elliot

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Thirty-one patients with stage III or IV diffuse histiocytic lymphoma were treated with cyclophosphamide, doxorubicin, vencristine, and prednisone (CHOP) at 3- or 4-week intervals for at least six cycles or until two cycles after complete remission (CR) was achieved. At the completion of therapy, CR was documented by examination of sites known to previously contain disease. After documentation of CR, patients were followed without maintenance therapy. Fifteen patients (48%) achieved CR, four (13%) had equivocal lymphangiograms on restaging but were otherwise free of disease, two (6%) died of unrelated causes during therapy, two (6%) developed central nervous system lymphoma during therapy and despite peripheral remission eventually died of the CNS disease, and eight (26%) had either partial or no response. Twelve of the 15 patients achieving CR remain disease-free with no therapy for 9+ to 43+ months. Three patients relapsed at 3, 4, and 23 months after discontinuation of therapy. Three of the four patients with equivocal restaging lymphangiograms remain without progressive disease with no therapy for 10+ to 24+ months. The projected median survival time for all patients is 41 months. The risks of long-term (maintenance) chemotherapy are considerable and include the induction of acute nonlymphoblastic leukemia. CHOP without maintenance therapy is able to induce long-term disease-free survival (and probable cure) in a significant number of patients with advanced diffuse histiocytic lymphoma.

Original languageEnglish (US)
Pages (from-to)649-654
Number of pages6
JournalCancer treatment reports
Volume64
Issue number4-5
StatePublished - Dec 1 1980

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Therapeutics
Maintenance Chemotherapy
Central Nervous System Diseases
Acute Myeloid Leukemia
Documentation
Disease-Free Survival
Lymphoma
Central Nervous System
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy. / Armitage, J. O.; Corder, M. P.; Leimert, J. T.; Dick, F. R.; Elliot, T. E.

In: Cancer treatment reports, Vol. 64, No. 4-5, 01.12.1980, p. 649-654.

Research output: Contribution to journalArticle

@article{93523a869fce4981be5d74123181f1f0,
title = "Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy",
abstract = "Thirty-one patients with stage III or IV diffuse histiocytic lymphoma were treated with cyclophosphamide, doxorubicin, vencristine, and prednisone (CHOP) at 3- or 4-week intervals for at least six cycles or until two cycles after complete remission (CR) was achieved. At the completion of therapy, CR was documented by examination of sites known to previously contain disease. After documentation of CR, patients were followed without maintenance therapy. Fifteen patients (48{\%}) achieved CR, four (13{\%}) had equivocal lymphangiograms on restaging but were otherwise free of disease, two (6{\%}) died of unrelated causes during therapy, two (6{\%}) developed central nervous system lymphoma during therapy and despite peripheral remission eventually died of the CNS disease, and eight (26{\%}) had either partial or no response. Twelve of the 15 patients achieving CR remain disease-free with no therapy for 9+ to 43+ months. Three patients relapsed at 3, 4, and 23 months after discontinuation of therapy. Three of the four patients with equivocal restaging lymphangiograms remain without progressive disease with no therapy for 10+ to 24+ months. The projected median survival time for all patients is 41 months. The risks of long-term (maintenance) chemotherapy are considerable and include the induction of acute nonlymphoblastic leukemia. CHOP without maintenance therapy is able to induce long-term disease-free survival (and probable cure) in a significant number of patients with advanced diffuse histiocytic lymphoma.",
author = "Armitage, {J. O.} and Corder, {M. P.} and Leimert, {J. T.} and Dick, {F. R.} and Elliot, {T. E.}",
year = "1980",
month = "12",
day = "1",
language = "English (US)",
volume = "64",
pages = "649--654",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4-5",

}

TY - JOUR

T1 - Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy

AU - Armitage, J. O.

AU - Corder, M. P.

AU - Leimert, J. T.

AU - Dick, F. R.

AU - Elliot, T. E.

PY - 1980/12/1

Y1 - 1980/12/1

N2 - Thirty-one patients with stage III or IV diffuse histiocytic lymphoma were treated with cyclophosphamide, doxorubicin, vencristine, and prednisone (CHOP) at 3- or 4-week intervals for at least six cycles or until two cycles after complete remission (CR) was achieved. At the completion of therapy, CR was documented by examination of sites known to previously contain disease. After documentation of CR, patients were followed without maintenance therapy. Fifteen patients (48%) achieved CR, four (13%) had equivocal lymphangiograms on restaging but were otherwise free of disease, two (6%) died of unrelated causes during therapy, two (6%) developed central nervous system lymphoma during therapy and despite peripheral remission eventually died of the CNS disease, and eight (26%) had either partial or no response. Twelve of the 15 patients achieving CR remain disease-free with no therapy for 9+ to 43+ months. Three patients relapsed at 3, 4, and 23 months after discontinuation of therapy. Three of the four patients with equivocal restaging lymphangiograms remain without progressive disease with no therapy for 10+ to 24+ months. The projected median survival time for all patients is 41 months. The risks of long-term (maintenance) chemotherapy are considerable and include the induction of acute nonlymphoblastic leukemia. CHOP without maintenance therapy is able to induce long-term disease-free survival (and probable cure) in a significant number of patients with advanced diffuse histiocytic lymphoma.

AB - Thirty-one patients with stage III or IV diffuse histiocytic lymphoma were treated with cyclophosphamide, doxorubicin, vencristine, and prednisone (CHOP) at 3- or 4-week intervals for at least six cycles or until two cycles after complete remission (CR) was achieved. At the completion of therapy, CR was documented by examination of sites known to previously contain disease. After documentation of CR, patients were followed without maintenance therapy. Fifteen patients (48%) achieved CR, four (13%) had equivocal lymphangiograms on restaging but were otherwise free of disease, two (6%) died of unrelated causes during therapy, two (6%) developed central nervous system lymphoma during therapy and despite peripheral remission eventually died of the CNS disease, and eight (26%) had either partial or no response. Twelve of the 15 patients achieving CR remain disease-free with no therapy for 9+ to 43+ months. Three patients relapsed at 3, 4, and 23 months after discontinuation of therapy. Three of the four patients with equivocal restaging lymphangiograms remain without progressive disease with no therapy for 10+ to 24+ months. The projected median survival time for all patients is 41 months. The risks of long-term (maintenance) chemotherapy are considerable and include the induction of acute nonlymphoblastic leukemia. CHOP without maintenance therapy is able to induce long-term disease-free survival (and probable cure) in a significant number of patients with advanced diffuse histiocytic lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0019206164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019206164&partnerID=8YFLogxK

M3 - Article

C2 - 7000347

AN - SCOPUS:0019206164

VL - 64

SP - 649

EP - 654

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4-5

ER -